NewAmsterdam Pharma (NASDAQ:NAMS) Posts Earnings Results, Misses Expectations By $0.04 EPS

NewAmsterdam Pharma (NASDAQ:NAMS) issued its quarterly earnings results on Wednesday. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04), FiscalAI reports. The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $1.88 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.05%.

Here are the key takeaways from NewAmsterdam Pharma’s conference call:

• European regulatory progress: Obicetrapib received a positive CHMP recommendation, with EMA approval and Menarini-led launches in the U.K. and Germany anticipated by late Q4 2026.
• PREVAIL remains the central catalyst. Management said blinded event rates are tracking favorably against BROADWAY and that an interim analysis could occur in Q1 2027, while retaining the option to continue the trial through the end of 2027 to maximize statistical power.
• The company highlighted broad lipid effects beyond LDL reduction, including more than 40% LDL lowering with obicetrapib monotherapy, roughly 60% with the ezetimibe fixed-dose combination, substantial HDL increases, and reductions in Lp(a) and small LDL particles. These claims remain dependent on ongoing outcomes validation.
• Commercial preparations are accelerating amid a growing lipid-treatment market, expanded treatment guidelines, and a large undertreated patient population. NewAmsterdam said it has more than $678 million in cash and has expanded its commercial and medical-affairs leadership ahead of potential launches.
• The company is advancing additional programs, including RUBENS in patients with diabetes and metabolic syndrome, REMBRANDT for plaque imaging with the fixed-dose combination, and SPINOZA to evaluate Alzheimer’s-related biomarkers in APOE4 carriers. These programs could broaden differentiation but remain investigational and are not yet established clinical benefits.

NewAmsterdam Pharma Stock Up 0.9%

Shares of NAMS stock traded up $0.25 during trading hours on Thursday, reaching $27.67. 1,649,399 shares of the company traded hands, compared to its average volume of 989,831. The firm has a 50-day moving average price of $31.64 and a 200 day moving average price of $32.56. NewAmsterdam Pharma has a 12-month low of $22.26 and a 12-month high of $42.21.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price target on the stock. Jefferies Financial Group restated a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Friday, July 17th. Finally, Royal Bank Of Canada lowered their price objective on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 105,000 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the sale, the chief accounting officer owned 24,353 shares in the company, valued at approximately $738,870.02. This trade represents a 81.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have sold 210,000 shares of company stock valued at $6,713,550. Corporate insiders own 12.74% of the company’s stock.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN boosted its holdings in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the period. Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $85,000. Persistent Asset Partners Ltd purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $138,000. The Manufacturers Life Insurance Company boosted its stake in NewAmsterdam Pharma by 5.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 10,868 shares of the company’s stock worth $197,000 after purchasing an additional 544 shares during the period. Finally, Guggenheim Capital LLC bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $224,000. 89.89% of the stock is currently owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.